Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash. This move brings Halda’s Regulated Induced Proximity Targeting Chimera (RIPTAC) platform to J&J’s oncology portfolio, supporting the development of oral,…
Continue reading...